Humacyte, Inc. - Common Stock, par value $0.0001 per share (HUMA)

CUSIP: 44486Q103

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class
Equity / Common Stock, par value $0.0001 per share
Total 13F shares
56,964,566
Total 13F value
$119,040,607
Holder snapshot 6 visible 7 signals
Share change
-3,714,556
Put/Call ratio
74%
SEC-reported price per share
$2.09
Number of holders
155
Value change
-$1,729,485
Number of buys
102
Open additional details 1 more signal available
Number of sells
63
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
269,769,473

Security key

44486Q103

Report period

Q2 2025

Institutions

155

Top holders

10

HUMA full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Previous quarter: Q1 2025 Humacyte, Inc. SEC filings Humacyte, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of HUMA - Humacyte, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FRESENIUS MEDICAL CARE HO...
Disclosed value leader
FRESENIUS MEDICAL CARE HO...
Comparable rows
15/15
Latest evidence
31 Mar 2025
3/4/5 13F Lead comparable stake: 6.8% Showing 1-6 of 15 holder rows.

Quick read

FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ leads the comparable SEC ownership view at 6.8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FRESENIUS MEDICAL CARE HOLDINGS INC /NY/'s linked filing trail.
Comparable ownership Top 5
FRESENIUS MEDICAL CARE HOLDINGS I... 6.8%
BlackRock, Inc. 3%
VANGUARD GROUP INC 2.4%
STATE STREET CORP 1.6%
HEIGHTS CAPITAL MANAGEMENT, INC 1.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
3/4/5
Former 10% Shareholder
3/4/5
6.8%
$21,792,154
18,312,735 shares
 — 26 Aug 2021
BlackRock, Inc.
13F
Company
13F
3%
$14,023,870
8,225,144 shares
 — 31 Mar 2025
VANGUARD GROUP INC
13F
Company
13F
2.4%
$11,252,397
6,599,646 shares
 — 31 Mar 2025
STATE STREET CORP
13F
Company
13F
1.6%
$7,273,474
4,265,967 shares
 — 31 Mar 2025
HEIGHTS CAPITAL MANAGEMENT, INC
13F
Company
13F
1.5%
$6,862,625
4,025,000 shares
 — 31 Mar 2025
Woodline Partners LP
13F
Company
13F
1.5%
$6,734,750
3,950,000 shares
 — 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
155
Shares
56,964,566
Rows available
155
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
162
Q2 2025 holders
155
Holder diff
-7
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .